Pacira BioSciences (PCRX) Restructuring Costs (2023 - 2024)
Pacira BioSciences' (PCRX) quarterly Restructuring Costs came in at $1.2 million in Q3 2024, up 589.6% year-on-year from $173000.0 in Q4 2023, and up 19.3% quarter-over-quarter from $1.0 million in Q2 2024.
Pacira BioSciences (PCRX) Restructuring Costs (2023 - 2024) Analysis & Trends
Pacira BioSciences' Restructuring Costs history runs 2 years deep, the most recent figure standing at $1.2 million for Q3 2024.
- On a quarterly basis, Restructuring Costs rose 589.6% year-over-year to $1.2 million in Q3 2024; TTM through Sep 2024 was $2.4 million, a N/A change from a year earlier, with the FY2017 full-year figure at $51.5 million, changed N/A from the prior year.
- Restructuring Costs improved to $1.2 million in Q3 2024 per PCRX's latest filing, from $1.0 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $1.2 million in Q3 2024 and bottomed at $173000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Pacira BioSciences | 1.05 Bn | 846.97 Mn | 140.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.19 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Sep 30, 2023 | 173,000.00 |